Videos

Panelists discuss how structured monitoring and interdisciplinary collaboration enable safe, effective integration of NK-targeted therapies into primary care.

Gus Alva, MD, reviews key 2025 psychiatry advances, including non-monoaminergic approaches to MDD and newer targets in schizophrenia care.

Dr Hatfield shares a case of a patient living in shared housing who was concerned about her housemates seeing her PrEP medication.

Panelists discuss how NK receptor antagonists can be strategically positioned as core nonhormonal options within the broader VMS treatment landscape.

Panelists discuss how NK receptor antagonism may improve mood and sleep quality, linking thermoregulation with broader emotional and cognitive health benefits.

Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.

Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.

Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

Larkin Larkin, MD, reviews treatment options for VMS, comparing hormone therapy effectiveness with antidepressants and new neurokinin antagonists.

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

Study author Daniel Jiang, MD, PhD, discusses data linking hormone therapy to increased autoimmune disease risk in postmenopausal women and clinical implications.

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.

Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.

Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.